drugset / Trial / NCT00685061

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

NCT00685061

Phase 4 Completed 90 enrolled University of Miami
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy vs. our conventional therapy in recipients of first cadaver (CAD) kidneys.

Timeline

Start
2002-11
Primary completion
2004-09
Completion
2005-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody
Subject Daclizumab Monoclonal antibody
Subject Thymoglobulin Protein / enzyme biologic

Indications

No indication recorded.